Skip to main content
Erschienen in: Neurotoxicity Research 1/2016

01.01.2016 | Original Article

Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis

verfasst von: Margherita Fabbri, Giorgio Leodori, Ricardo M. Fernandes, Roongroj Bhidayasiri, Maria Jose Marti, Carlo Colosimo, Joaquim J. Ferreira

Erschienen in: Neurotoxicity Research | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The formation of neutralizing antibodies (NAbs) directed specifically against the active neurotoxin part of the botulinum neurotoxin (BoNT) complex is often cited as a major cause of secondary non-responsiveness (SnR) to treatment. This systematic and meta-analytic review evaluates the frequency of NAbs among patients treated with BoNT therapy for any clinical indication. A comprehensive database search strategy was designed to retrieve relevant clinical data from the published literature up to April 2013. All English-language publications that analyzed NAbs prevalence in more than ten patients were included, regardless of BoNT formulation, assay method, and study design. For the meta-analysis, patients were divided into three categories: secondary non-response (SnR) patients, clinically responding patients and all patients, independently of BoNT responsiveness. The meta-analysis included 61 studies reporting data for 8525 patients; 4972 dystonic patients, 1170 patients with spasticity, 294 patients with urologic indications, 396 patient with hyperhidrosis, 1659 patients with glabellar line, and 34 patients with hypersalivation. Among the “all patients” group NAbs frequency was 20 % for dystonia, 5.9 % for spasticity, and 2.7 % for urologic patients and 1.1 % for other conditions. The prevalence of NAbs was lower (3.5 %) among clinically responding patients and higher in 53.5 % SnR patients. About a half of patients with SnR do not have NAbs. NAbs was high among patients treated with RIMA but it was not associated with clinical non-responsiveness. Meta-analysis of the frequency of NAbs and SnR are limited by the heterogeneity of study design and reported outcomes. Indeed the analysis of several factors that can influence the development of NAbs, i.e., MHC of patients, frequency and site of injection, injection technique, cumulative dose, and toxin denaturation, was not specifically evaluated due to the paucity and heterogeneity of data. The identification of all these missing data should be taken into account in order to improve the methodology of future studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR (2011) Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216(7):782–792. doi:10.1016/j.imbio.2010.12.009 PubMedCrossRef Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR (2011) Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216(7):782–792. doi:10.​1016/​j.​imbio.​2010.​12.​009 PubMedCrossRef
Zurück zum Zitat Borodic G, Johnson E, Goodnough M, Schantz E (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46(1):26–29PubMedCrossRef Borodic G, Johnson E, Goodnough M, Schantz E (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46(1):26–29PubMedCrossRef
Zurück zum Zitat Brin MF (2007) Treatment of dystonia. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Lippincott Williams & Wilkins, Philadelphia, pp 348–355 Brin MF (2007) Treatment of dystonia. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Lippincott Williams & Wilkins, Philadelphia, pp 348–355
Zurück zum Zitat Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, Group CDBS (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23(10):1353–1360. doi:10.1002/mds.22157 PubMedCrossRef Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, Group CDBS (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23(10):1353–1360. doi:10.​1002/​mds.​22157 PubMedCrossRef
Zurück zum Zitat Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y (2012) Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 35(5):215–223. doi:10.1097/WNF.0b013e318263163c PubMedCrossRef Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y (2012) Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 35(5):215–223. doi:10.​1097/​WNF.​0b013e318263163c​ PubMedCrossRef
Zurück zum Zitat Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21(10):1737–1741. doi:10.1002/mds.21051 PubMedCrossRef Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21(10):1737–1741. doi:10.​1002/​mds.​21051 PubMedCrossRef
Zurück zum Zitat Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60(4):742–750. doi:10.1016/j.eururo.2011.07.002 PubMedCrossRef Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60(4):742–750. doi:10.​1016/​j.​eururo.​2011.​07.​002 PubMedCrossRef
Zurück zum Zitat Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ (2007) Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 44(5):1029–1041. doi:10.1016/j.molimm.2006.03.011 PubMedCrossRef Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ (2007) Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 44(5):1029–1041. doi:10.​1016/​j.​molimm.​2006.​03.​011 PubMedCrossRef
Zurück zum Zitat Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19:S92–S100PubMedCrossRef Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19:S92–S100PubMedCrossRef
Zurück zum Zitat Hanna PA, Jankovic J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50(6):1624–1629PubMedCrossRef Hanna PA, Jankovic J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50(6):1624–1629PubMedCrossRef
Zurück zum Zitat Hatheway CL, Dang C (1994) Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 93–108 Hatheway CL, Dang C (1994) Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 93–108
Zurück zum Zitat Jankovic J, Schwartz KS (1991) Clinical correlates of response to botulinum toxin injections. Arch Neurol 48(12):1253–1256PubMedCrossRef Jankovic J, Schwartz KS (1991) Clinical correlates of response to botulinum toxin injections. Arch Neurol 48(12):1253–1256PubMedCrossRef
Zurück zum Zitat Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45(9):1743–1746PubMedCrossRef Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45(9):1743–1746PubMedCrossRef
Zurück zum Zitat Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186–1188PubMedCrossRef Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186–1188PubMedCrossRef
Zurück zum Zitat Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ (2006) Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67(12):2233–2235. doi:10.1212/01.wnl.0000249308.66959.43 PubMedCrossRef Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ (2006) Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67(12):2233–2235. doi:10.​1212/​01.​wnl.​0000249308.​66959.​43 PubMedCrossRef
Zurück zum Zitat Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265–274PubMedCrossRef Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265–274PubMedCrossRef
Zurück zum Zitat Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, de Yebenes Garcia, Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT (2001) Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108(5):1062–1071PubMedCrossRef Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, de Yebenes Garcia, Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT (2001) Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108(5):1062–1071PubMedCrossRef
Zurück zum Zitat Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32(4):213–218. doi:10.1097/WNF.0b013e3181914d0a PubMedCrossRef Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32(4):213–218. doi:10.​1097/​WNF.​0b013e3181914d0a​ PubMedCrossRef
Zurück zum Zitat Mezaki T, Kaji R, Hamano T, Nagamine T, Shibasaki H, Shimizu T, Kimura J (1994) Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J Neurol Neurosurg Psychiatrym 57(12):1535–1537CrossRef Mezaki T, Kaji R, Hamano T, Nagamine T, Shibasaki H, Shimizu T, Kimura J (1994) Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J Neurol Neurosurg Psychiatrym 57(12):1535–1537CrossRef
Zurück zum Zitat Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43(9):1715–1718PubMedCrossRef Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43(9):1715–1718PubMedCrossRef
Metadaten
Titel
Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis
verfasst von
Margherita Fabbri
Giorgio Leodori
Ricardo M. Fernandes
Roongroj Bhidayasiri
Maria Jose Marti
Carlo Colosimo
Joaquim J. Ferreira
Publikationsdatum
01.01.2016
Verlag
Springer US
Erschienen in
Neurotoxicity Research / Ausgabe 1/2016
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI
https://doi.org/10.1007/s12640-015-9565-5

Weitere Artikel der Ausgabe 1/2016

Neurotoxicity Research 1/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.